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OBJECTIVE
A common variant rs236918 in the PCSK7 gene has the strongest association with
iron homeostasis and is related to insulin resistance. Dietary carbohydrate (CHO)
modulates the genetic effect on insulin resistance. We examined whether 2-year
weight-loss diets modify the effect of PCSK7 genetic variants on changes in fasting
insulin levels and insulin resistance in a randomized, controlled trial.
RESEARCH DESIGN AND METHODS
Data were analyzed in the Preventing Overweight Using Novel Dietary Strategies
(POUNDS LOST) trial, which is a randomized, controlled 2-year weight-loss trial
using diets that differed in macronutrient proportions. PCSK7 rs236918 was geno-
typed in 730 overweight or obese adults (80% whites) in this trial. We assessed
the progression in fasting insulin and glucose levels, and insulin resistance by
genotypes.
RESULTS
During the 6-month weight-loss phase, the PCSK7 rs236918 G allele was signif-
icantly associated with greater decreases in fasting insulin levels in the high–
dietary CHO group (P for interaction = 0.04), while the interaction for changes in
HOMA-insulin resistance (HOMA-IR) (P for interaction = 0.06) did not reach
signiﬁcant levels in white subjects. The G allele was signiﬁcantly associated
with a greater decrease in fasting insulin levels and HOMA-IR in response to
high dietary CHO levels (P = 0.02 and P = 0.03, respectively). From 6 months to
2 years (weight-regain phase), the interactions became attenuated due to the
regaining of weight (P for interactions = 0.08 and 0.06, respectively). In addition,
we observed similar and even stronger results in the whole-study samples from
the trial.
CONCLUSIONS
Our data suggest that PCSK7 genotypes may interact with dietary CHO intake on
changes in insulin sensitivity in the white Americans.
Compelling evidence has shown that elevated body iron stores might be associated
with insulin resistance (1) and type 2 diabetes risk (2). Elevated iron stores may
interfere with hepatic insulin extraction, leading to peripheral hyperinsulinemia (3).
Several epidemiological studies (4,5) have revealed that genetic variants in iron
store–related pathways were directly associated with or interacted with diets in
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relation to type 2 diabetes. A recent
genome-wide association study (GWAS)
(6) identiﬁed a locus near the proprotein
convertase subtilisin/kexin type 7 gene
(PCSK7) (rs236918), which shows the
strongest relation with markers of body
iron stores. The function of PCSK7 in
iron homeostasis was demonstrated in
studies by Guillemot et al. (7) and
Schwienbacher et al. (8), in which it was
found that PCSK7 modulated hepcidin
expression by directly inﬂuencing soluble
hemojuvelin levels. In addition, PCSK7
may act as an important mediator of
adipocyte differentiation (9), and poten-
tially affect obesity and relatedmetabolic
disorders such as insulin resistance. How-
ever, whether PCSK7 genotype is related
to insulin resistance or type 2 diabetes
risk remains unclear.
Previous gene-diet interaction analy-
sis has shown that dietary carbohydrate
(CHO) modulates the effect of genetic
variants on insulin resistance (10). In
addition, high-CHO feeding restored
PCSK subtype mRNA expression after
24 h of fasting in mice (11). Therefore,
in the current study, we aimed to exam-
ine whether the PCSK7 genotype affects
long-term changes in fasting insulin and
insulin resistance, and to test whether a
2-year weight-loss diet might modify
the effects of PCSK7 genotype on the
long-term changes in insulin resistance
over the course of the intervention. The
identiﬁcation of gene-diet interactions
may help to elucidate the mechanisms
of the development of insulin resistance.
RESEARCH DESIGN AND METHODS
Study Participants
The Preventing Overweight Using Novel
Dietary Strategies (POUNDS LOST) trial
(clinical trial reg. no. NCT00072995,
clinicaltrials.gov) is a 2-year randomized
clinical trial comparing the effects of
energy-reduced diets with different
compositions of fat, protein, and CHO
on weight change, which was conducted
at Boston, MA, and Baton Rouge, LA, in
2004–2007. The study was approved by
the human subjects committee at the
Harvard School of Public Health and
Brigham and Women’s Hospital, Boston,
MA; the PenningtonBiomedical Research
Center of the Louisiana State University,
Baton Rouge, LA; and a data and safety
monitoring board appointed by the Na-
tional Heart, Lung, and Blood Institute.
All participants gave written informed
consent. Detailed information on the
study design and methods has been pre-
viously described (12). Major criteria for
study exclusion were the presence of di-
abetes or unstable cardiovascular dis-
ease, the use of medications that
affect body weight, and insufﬁcient mo-
tivation. A total of 811 overweight
or obese subjects (BMI $25 and #40
kg/m2) who were 30–70 years of age
were randomly assigned to one of the
following four diets; the target percent-
ages of energy derived from fat, pro-
tein, and CHO in the four diets were,
respectively, 20%, 15%, and 65%; 20%,
25%, and 55%; 40%, 15%, and 45%; and
40%, 25%, and 35%. In the current study,
participants from the diet groups were
combined for the comparison of low-
CHO diets (35% and 45%) and high-CHO
diets (55% and 65%), and for the com-
parison of the lowest-CHO diets (35%)
and the highest-CHO diets (65%). In the
POUNDS LOST trial, the high-CHO/low-
CHO diets are indeed the same as the
low-fat/high-fat diets. After 2 years,
80% of the participants (n = 645) had
completed the trial. Among those partic-
ipants who had genotyping data (n =
730), 594 participants actually com-
pleted the trial. To assess the dietary ad-
herence across the intervention, dietary
intake was assessed in a random sample
of 50% of the participants, by a review of
the 5-day diet record at baseline and by
24-h recall during a telephone interview
on 3 nonconsecutive days at 6 months
and at 2 years.
Measurements
Body weight and waist circumference
were measured in the morning before
breakfast at baseline, 6 months, and
2 years. Height was measured at base-
line. BMI was calculated as weight (in
kilograms)/height2 (in square meters).
Fasting blood samples were collected
at baseline, 6 months, and 2 years;
and serum glucose and insulin levels
were measured at the clinical labora-
tory at the Pennington Biomedical Re-
search Center. Insulin resistance was
estimated by HOMA-insulin resistance
(HOMA-IR) calculated by the following
equation: (fasting insulin [in microunits
per milliliter] 3 [fasting glucose [in milli-
grams per deciliter]/18.01])/22.5 (13).
Genotyping
DNA was extracted from the buffy coat
fraction of centrifuged blood using the
QIAamp Blood Kit (Qiagen, Chatsworth,
CA). Single nucleotide polymorphism
(SNP) rs236918 in the PCSK7 gene was
selected because the PCSK7 association
with soluble transferrin receptor gener-
ation and/or iron homeostasis was the
most signiﬁcant (rs236918) in a meta-
analysis of ﬁve GWASs (6). The SNP was
genotyped successfully in 730 of 811 total
participants using the OpenArray SNP
Genotyping System (BioTrove, Woburn,
MA). The genotype success rate was
99% in available DNA samples. Replicated
quality control samples (10%) were in-
cluded in every genotyping plate with
.99% concordance (14).
Statistical Analysis
In the ﬁnal analysis, we included only
those participants who had genotype
data (n = 730). The primary end points
for this study were changes in fasting
insulin levels and insulinresistance over
the course of the intervention. General
linear models (PROC GLM) for continu-
ous variables and the x2 test (PROC
FREQ) for categorical variables were
applied for the comparison according
to genotype groups at baseline. We
compared the changes in the primary
end points, biomarkers of adherence,
and nutrient intakes across genotype
groups at 6 months and 2 years using
generalized linear models. To test for
interactions, we examined genotype
and genotype-diet interactions as inde-
pendent predictors of changes in the
weight-loss phase (from baseline to 6
months) and weight-regain phase (pa-
tients generally regain lost weight from
6 months to 2 years) (12), adjusted for
age, sex, ethnicity, baseline BMI, weight
change, and the baseline value for the
respective outcome trait in the general-
ized linear models. All reported P values
were nominal. A two-sided test and a
P value of 0.05 were considered sta-
tistically signiﬁcant. We used Quanto
version 1.2.4 (University of Southern
California, Los Angeles, CA; http://
hydra.usc.edu.gxe) to estimate the de-
tectable effect sizes of genotype-diet in-
teractions. The study had 80% power to
detect the gene-diet interaction by ac-
counting for a 16.7% change in fasting
insulin levels, and an 18.4% change in
HOMA-IR at a signiﬁcance level of 0.05.
Statistical analyses were performed
with SAS version 9.1 (SAS Institute,
Inc., Cary, NC).
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RESULTS
Characteristics of Study Population
Baseline characteristics of participants
according to the PCSK7 rs236918 geno-
type are presented in Table 1. The minor
allele frequency (G allele) was 0.12 in the
total population. The genotype frequen-
cies were signiﬁcantly different by eth-
nicity but not sex. Body weight, BMI,
waist circumference, fasting glucose
and insulin levels, and HOMA-IR were
not related to PCSK7 genotype at base-
line. The association of PCSK7 genotype
with fasting glucose and insulin levels
and HOMA-IR was not signiﬁcant after
further adjustment of baseline BMI. No
associations of genotype with weight
loss and waist loss at 6 months and 2
years were observed.
Table 2 shows dietary intake and adher-
ence markers of the participants in white
subjects. We assessed the biomarkers
to conﬁrm the dietary adherence. There
were no signiﬁcant differences in mean
values of nutrient intakes and biomarkers
of adherence at 6 months and 2 years
across the PCSK7 rs236918 genotype
(P. 0.05). Total energy, fat, protein, and
CHO levels, and changes in urinary nitro-
gen levels and respiratory quotient (bio-
markers of adherence) conﬁrmed that
differences in macronutrient intake
among the groups were consistent with
those recoded in the dietary reports, and
that participants modiﬁed their intakes
of macronutrients in the direction of the
goals, although the targets were not fully
achieved (12). Dietary intake and adher-
ence markers of the participants in the
whole population are shown in Supple-
mentary Table 1.
Genotype Effects on Change in Insulin
Resistance During Weight-Loss Phase
(0–6 Months)
We primarily analyzed the data in the
white subgroup (80% of the study sam-
ples). During the 6-month intervention,
we found a signiﬁcant interaction be-
tween PCSK7 rs236918 genotype and
dietary CHO levels on changes in fasting
insulin levels after adjustment for age,
sex, ethnicity, weight change, and base-
line values for respective phenotypes
(P for interaction = 0.04), while the in-
teraction for changes in HOMA-IR (P for
interaction = 0.06) did not reach a sig-
niﬁcant level (Fig. 1). In the adjusted
model, the G allele was signiﬁcantly
associated with a greater decrease in
fasting insulin levels and HOMA-IR in
response to high dietary CHO levels
(P = 0.02 and P = 0.03, respectively).
Further adjustment for baseline BMI
and dietary protein LEVELS in the
model yielded similar results. We fur-
ther analyzed the effects of the inter-
action of the PCSK7 rs236918 genotype
and the two most extreme CHO diets
(35% vs. 65%) on fasting insulin levels
and insulin resistance. We did not ob-
serve signiﬁcant results after adjustment
for age, sex, ethnicity, baseline BMI,
weight change, and baseline values for
respective phenotypes.
In thewhole-study samples, we found
similar and even stronger interactions
between PCSK7 rs236918 genotype
and dietary CHO on changes in fasting
insulin levels and HOMA-IR (both P for
interactions = 0.001). In the adjusted
model, the G allele was signiﬁcantly as-
sociated with a greater decrease in fast-
ing insulin levels and HOMA-IR in
response to high dietary CHO levels
(P = 0.004 and P = 0.012, respectively),
whereas opposite genotype effects on
changes in insulin levels and insulin re-
sistance were observed in the low–
dietary CHO group during the 6-month
intervention (P = 0.002 and P = 0.008,
respectively) (Supplementary Fig. 1).
Genotype Effects on Change in Insulin
Resistance DuringWeight-Regain Phase
(7–24 Months)
In the white subgroup, between 7 and
24 months, the interactions between
PCSK7 rs236918 genotype and dietary
CHO on reversion in fasting insulin level
(P for interaction = 0.08) and HOMA-IR
(P for interaction = 0.06) became atten-
uated after adjustment for age, sex, eth-
nicity, baseline BMI, weight change, and
baseline values for respective pheno-
types (Fig. 1). No interactions were ob-
served between the PCSK7 genotype
and other macronutrients.
Table 1—Characteristics by PCSK7 gene variant (rs236918) at baseline and
changes at 6 months and 2 years in participants in the POUNDS LOST study
Characteristics CC (n = 566) CG (n = 153) GG (n = 11) P value*
Age, years 50.6 6 9.4 51.8 6 9.0 50.6 6 9.0 0.46
Sex 0.05
Female 344 (77.3) 98 (22.0) 3 (0.7)
Male 222 (77.9) 55 (19.3) 8 (2.8)
Race or ethnicity ,0.0001
White 473 (81.27) 102 (17.5) 7 (1.2)
Black 76 (67.9) 35 (31.3) 1 (0.9)
Hispanic 15 (60.0) 9 (36.0) 1 (4.0)
Asian or other 2 (18.2) 7 (63.6) 2 (18.2)
Dietary intake per day
Energy, kcal 1,958 6 529 2,009 6 658 2,192 6 610 0.24
CHO, % 45 6 8 44 6 7 44 6 8 0.06
Fat, % 37 6 6 37 6 6 37 6 7 0.41
Protein, % 18 6 3 18 6 4 18 6 5 0.45
Weight, kg 92.9 6 15.6 94.5 6 15.5 91.4 6 11.5 0.45
BMI, kg/m2 32.5 6 3.9 33.1 6 3.7 31.9 6 3.2 0.32
Insulin (lU/mL)† 12.1 6 7.8 12.8 6 7.6 12.6 6 7.0 0.41
HOMA-IR† 2.8 6 2.0 3.0 6 1.9 2.9 6 1.7 0.38
Insulin change†
At 6 months 20.26 6 0.45 20.26 6 0.45 20.25 6 0.52 0.88
2 years 20.15 6 0.46 20.12 6 0.43 20.10 6 0.68 0.72
HOMA-IR change†
6 months 20.28 6 0.50 20.29 6 0.49 20.25 6 0.58 0.54
2 years 20.12 6 0.50 20.10 6 0.46 20.06 6 0.79 0.63
Weight loss at 6 months, kg 26.8 6 5.6 26.2 6 5.4 23.2 6 5.6 0.14
Waist loss at 6 months, cm 26.9 6 6.2 26.8 6 5.8 23.1 6 5.2 0.47
Weight loss at 2 years, kg 24.0 6 7.4 24.1 6 7.1 0.2 6 6.3 0.58
Waist loss at 2 years, cm 25.7 6 7.6 25.6 6 7.6 22.2 6 7.2 0.56
Data are expressed as the mean 6 SD or n (%) . *P values were calculated by x2 test for
categorical variables, and by F tests after adjustment for age, sex, and ethnicity for continuous
variables. †These variables were log transformed before analysis. The model was adjusted for
baseline BMI.
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In the whole-study samples, we found
signiﬁcant interactions between PCSK7
rs236918 and dietary CHO on a return
to or toward baseline levels of fasting
insulin and HOMA-IR after adjustment
for age, sex, ethnicity, weight change,
and baseline values for respective phe-
notypes (P for interactions = 0.054 and
0.034, respectively). In the adjusted
model, the G allele was associated
with greater reversion of fasting insulin
levels and HOMA-IR in response to high
dietary CHO levels (P = 0.028 and P =
0.027, respectively) (Supplementary
Fig. 1). However, we did not observe
signiﬁcant differences in reversion
of fasting insulin levels and HOMA-IR
between genotypes in response to
low dietary CHO levels from 6 months
to 2 years (P = 0.459 and P = 0.375, re-
spectively). Further analysis of the in-
teraction between PCSK7 rs236918
genotype and the two most extreme
CHO diets on insulin level and insulin
resistance yielded signiﬁcant results
(P for interaction = 0.01 and 0.006, re-
spectively) after adjustment for age,
sex, ethnicity, baseline BMI, weight
change, and baseline values for respec-
tive phenotypes.
Trajectory of Changes in Fasting
Insulin and HOMA-IR
We then used linear mixed models to
assess the genotype by time effect
over the 2-year intervention. We found
that study participants with the G allele
had a greater improvement of fasting
insulin levels and HOMA-IR than those
without the G allele across the 2-year
intervention in the high–dietary CHO
group in the white and whole popula-
tions. Interestingly, participants with
the G allele had greater increases of
fasting insulin levels and HOMA-IR
than those without the G allele from 6
months to 2 years during the interven-
tion in the high–dietary CHO group (Sup-
plementary Fig. 2).
CONCLUSIONS
In the 2-year randomized weight-loss in-
tervention trial, we observed that die-
tary CHO modiﬁed the effect of PCSK7
rs236918 on changes in fasting insulin
levels in the white subgroup and in the
whole-study samples. Individuals with
the PCSK7 rs236918 G allele might ben-
eﬁt more from reductions in fasting in-
sulin levels and insulin resistance than
those without this allele by choosing a
high dietary CHO level during the
weight-loss phase.
PCSK7 rs236918 was recently identi-
ﬁed to have the strongest association
with markers of body iron store (6),
which has been associated with insulin
resistance and the risk of T2D (1,2,15).
PCSK7 might affect the iron stores (16)
and subsequently interfere with hepatic
insulin extraction, leading to hyperinsu-
linemia (3,15).
During the weight-loss phase, we ob-
served that the effect of PCSK7 rs236918
on changes in fasting insulin levels was
Table 2—Nutrient intake and biomarkers of adherence according to PCSK7 rs236918 at 6 months and 2 years in white subjects
At 6 months At 2 years
CC CG GG CC CG GG
Dietary intake per day*
Energy, kcal 1,631 6 480 1,674 6 524 1,713 6 261 1,565 6 500 1,507 6 494 1,700 6 634
CHO, % 50 6 10 48 6 11 41 6 4 49 6 10 47 6 11 43 6 8
Fat, % 30 6 8 31 6 8 35 6 4 31 6 8 31 6 9 38 6 6
Protein, % 20 6 4 22 6 6 21 6 6 20 6 4 20 6 6 21 6 4
Biomarkers of adherence
Urinary nitrogen, g† 11.6 6 4.7 12.1 6 3.9 12.0 6 6.3 11.9 6 4.6 12.5 6 4.2 11.9 6 4.4
Respiratory quotient‡ 0.84 6 0.04 0.84 6 0.05 0.84 6 0.03 0.83 6 0.04 0.83 6 0.05 0.84 6 0.04
Data are expressed as the mean 6 SD. *Data were included for 5–268 participants per diet group at 6 months, and 4–140 participants at 2 years.
†Datawere included for 8–420 participants per diet group at 6months, and 9–362 participants at 2 years. ‡Datawere included for 8–420 participants
per diet group at 6 months, and 5–292 participants at 2 years.
Figure 1—Effects of PCSK7 rs236918 genotype and CHO diets on changes and reversion in fasting
insulin levels and HOMA-IR during the 2-year intervention in white Americans. Fasting insulin
levels and HOMA-IR were log transformed before analysis. P values are adjusted for age, sex,
ethnicity, weight change, and baseline values for respective phenotypes.
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signiﬁcantly modiﬁed by dietary CHO.
The participants with PCSK7 rs236918
G allele had a greater decrease in fasting
insulin when consuming a high-CHO
diet. The mechanism is not fully under-
stood. However, CHO-rich foods with
low glycemic index were used in the
present intervention. A previous study
(17) has shown that consumption of
low–glycemic index foods reduces the
risk of type 2 diabetes. A rodent study
(11) found that high–dietary CHO re-
feeding restored PCSK subtype mRNA
expression after 24 h of fasting. There-
fore, we hypothesize that the CHO diet
with low glycemic index might differen-
tially regulate the gene expression in the
PCSK7-involved pathway or in insulin-
related metabolic pathways according
to the genotypes. To date, there are no
functional data supporting a causal var-
iant in the PCSK7 gene. Our further
assessment showed that the PCSK7 var-
iant rs236918was not in linkage disequi-
librium with GWAS-identiﬁed loci in 11q
that might inﬂuence insulin-related
traits. Therefore, further studies are re-
quired to detect the causal variant in the
future.
During weight-regain phase, the
rs236918 G allele was marginally associ-
ated with greater reversion of insulin
levels and HOMA-IR toward baseline.
As we observed previously, the geno-
type effects on insulin resistance (14),
blood pressure (18), and body weight
(19) showed “reversion” patterns during
weight regain in the POUNDS LOST trial.
This reversion may be partly due to di-
minished adherence to dietary interven-
tion, similar to other weight-loss trials
(20–22). Our data suggest that individu-
als with the G allele might be more sen-
sitive to the alterations in dietary intake
regarding changes in insulin sensitivity.
To the best of our knowledge, this is
the ﬁrst study to investigate interac-
tions between a PCSK7 genetic variant
and dietary CHO on insulin resistance
in a large and long-term randomized
weight-loss trial. There is no evidence
that PCSK7 genetic variant rs236918
tags in other ethnicities; therefore, we
analyzed the white Americans sepa-
rately, and subsequently combined
all ethnicities as well. Our ﬁndings
suggest a new insight into the use of
PCSK7 genetic variant in improving per-
sonalized dietary interventions for indi-
viduals with diabetes. Importantly, this
large sample trial had a high rate of re-
tention and the sensitivity to detect small
changes in body weight. Furthermore,
the population was diverse with respect
to age, income, and geography. Thus, the
ﬁndings should be directly applicable to
clinical recommendations and the devel-
opment of population-wide recommen-
dations by public health ofﬁcials (12).
However, several limitations need to be
considered when interpreting our ﬁnd-
ings. First, it is difﬁcult to distinguish
which macronutrient plays the key role
behind the observed interactions be-
cause increased CHO intake reﬂects de-
creased fat intake. Thus, either CHO or
dietary fat may modulate the effect of
the PCSK7 rs236918. Second, the power
to detect the effect of genotype on in-
sulin resistance in response to the real
difference in macronutrients intake was
reduced because of the decline of adher-
ence to various diets after 6 months,
which is similar to most of the long-
term diet intervention trials reported
(14,23). Finally, 80% of the participants
in our study arewhite, and further studies
are required to determine whether our
ﬁndings are generalizable to other ethnic
groups. Furthermore, the minor allele
frequency of rs236918 varies across eth-
nicities; we acknowledge that further
PCSK7 genotype–directed clinical trials
are required to replicate our ﬁndings in
diverse populations, although the ran-
domized clinical trial is thought to be
the idealmodel to test gene-environment
interactions.
In conclusion, we found that individ-
uals with the PCSK7 rs236918 G allele
might obtain more beneﬁt from the im-
provement of insulin resistance during
the 6-month intervention. Future inter-
vention studies on the basis of speciﬁc
genotypes (e.g., PCSK7 rs236918) are
needed to evaluate the signiﬁcance of
using genetic information in guiding di-
etary interventions. Our ﬁndings lend
support to the need for personalized
nutrition advice in the future.
Acknowledgments. The authors thank all
participants in the trial for their dedication
and contribution to the research.
Funding. This study was supported by grants
from the National Heart, Lung, and Blood
Institute (HL-071981), the Boston Obesity Nu-
trition Research Center (DK-46200), the Na-
tional Institute of Diabetes and Digestive
and Kidney Diseases (DK-091718), the
National Natural Science Foundation of China
(NNSFC30972453), and the Program for New
Century Excellent Talents in University (NCET-
10–0420). L.Q. was the recipient of an American
Heart Association Scientist Development Award
(0730094N).
Duality of Interest. No potential conﬂicts of
interest relevant to this article were reported.
Author Contributions. T.H. and Q.Q. contrib-
uted to the study concept and design; the
acquisition, analysis, and interpretation of the
data; the statistical analysis; and the drafting
and critical revision of the manuscript. J.H.
contributed to the study concept and design;
the acquisition, analysis, and interpretation of
the data; and the drafting and critical revision
of the manuscript. Y.L. contributed to the
study concept and design and the critical
revision of the manuscript. G.A.B. and J.R.
contributed to the study concept and design
and the critical revision of the manuscript and
were involved in the collection and analysis of
the data and the funding of the initial project.
F.M.S. contributed to the study concept and
design, the critical revision of the manuscript,
and administration, material support, and
study supervision and was involved in the
collection and analysis of the data and the
funding of the initial project. L.Q. contributed
to the study concept and design; the acquisi-
tion, analysis, and interpretation of the data;
the drafting and critical revision of the manu-
script; and administration, material support,
and study supervision. L.Q. is the guarantor of
this work and, as such, had full access to all the
data in the study and takes responsibility for
the integrity of the data and the accuracy of
the data analysis.
References
1. Jehn M, Clark JM, Guallar E. Serum ferritin
and risk of the metabolic syndrome in U.S.
adults. Diabetes Care 2004;27:2422–2428
2. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N,
Hu FB. Body iron stores in relation to risk of type
2 diabetes in apparently healthy women. JAMA
2004;291:711–717
3. Ferrannini E. Insulin resistance, iron, and the
liver. Lancet 2000;355:2181–2182
4. Qi L, Meigs J, Manson JE, et al. HFE genetic
variability, body iron stores, and the risk of type
2 diabetes in U.S. women. Diabetes 2005;54:
3567–3572
5. Gan W, Guan Y, Wu Q, et al. Association of
TMPRSS6 polymorphisms with ferritin, hemo-
globin, and type 2 diabetes risk in a Chinese
Han population. Am J Clin Nutr 2012;95:626–
632
6. Oexle K, Ried JS, Hicks AA, et al. Novel
association to the proprotein convertase
PCSK7 gene locus revealed by analysing soluble
transferrin receptor (sTfR) levels. Hum Mol
Genet 2011;20:1042–1047
7. Guillemot J, Canuel M, Essalmani R, Prat A,
Seidah NG. Implication of the proprotein con-
vertases in iron homeostasis: proprotein con-
vertase 7 sheds human transferrin receptor 1
and furin activates hepcidin. Hepatology 2013;
57:2514–2524
8. Schwienbacher C, Seraﬁn A, Zanon A,
Pramstaller PP, Pichler I, Hicks AA. Involve-
ment of proprotein convertase PCSK7 in the
care.diabetesjournals.org Huang and Associates 443
regulation of systemic iron homeostasis. Hepa-
tology 2013;58:1860–1861
9. Croissandeau G, Basak A, Seidah NG,
Chre´tien M, Mbikay M. Proprotein convertases
are important mediators of the adipocyte dif-
ferentiation of mouse 3T3-L1 cells. J Cell Sci
2002;115:1203–1211
10. Smith CE, Arnett DK, Corella D, et al.
Perilipin polymorphism interacts with satu-
rated fat and carbohydrates to modulate insu-
lin resistance. Nutr Metab Cardiovasc Dis 2012;
22:449–455
11. Costet P, Cariou B, Lambert G, et al.
Hepatic PCSK9 expression is regulated by nutri-
tional status via insulin and sterol regulatory
element-binding protein 1c. J Biol Chem 2006;
281:6211–6218
12. Sacks FM, Bray GA, Carey VJ, et al. Com-
parison of weight-loss diets with different com-
positions of fat, protein, and carbohydrates. N
Engl J Med 2009;360:859–873
13. Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF, Turner RC. Homeo-
stasis model assessment: insulin resistance and
beta-cell function from fasting plasma glucose
and insulin concentrations in man. Diabetologia
1985;28:412–419
14. Qi Q, Bray GA, Smith SR, Hu FB, Sacks FM,
Qi L. Insulin receptor substrate 1 gene variation
modiﬁes insulin resistance response to weight-
loss diets in a 2-year randomized trial: the
Preventing Overweight Using Novel Dietary
Strategies (POUNDS LOST) trial. Circulation
2011;124:563–571
15. Gabrielsen JS, Gao Y, Simcox JA, et al.
Adipocyte iron regulates adiponectin and insu-
lin sensitivity. J Clin Invest 2012;122:3529–3540
16. Nelsen SM, Christian JL. Site-speciﬁc cleav-
age of BMP4 by furin, PC6, and PC7. J Biol Chem
2009;284:27157–27166
17. Brand-Miller J, Hayne S, Petocz P, Colagiuri
S. Low-glycemic index diets in the management
of diabetes: a meta-analysis of randomized con-
trolled trials. Diabetes Care 2003;26:2261–2267
18. Zhang X, Qi Q, Liang J, Hu FB, Sacks FM, Qi
L. Neuropeptide Y promoter polymorphism
modiﬁes effects of a weight-loss diet on 2-year
changes of blood pressure: the preventing over-
weight using novel dietary strategies trial. Hy-
pertension 2012;60:1169–1175
19. Xu M, Qi Q, Liang J, et al. Genetic de-
terminant for amino acid metabolites and
changes in body weight and insulin resistance
in response to weight-loss diets: the Preventing
Overweight Using Novel Dietary Strategies
(POUNDS LOST) trial. Circulation 2013;127:
1283–1289
20. Foster GD, Wyatt HR, Hill JO, et al. A
randomized trial of a low-carbohydrate diet
for obesity. N Engl J Med 2003;348:2082–2090
21. Dansinger ML, Gleason JA, Grifﬁth JL,
Selker HP, Schaefer EJ. Comparison of the At-
kins, Ornish, Weight Watchers, and Zone diets
for weight loss and heart disease risk reduction:
a randomized trial. JAMA 2005;293:43–53
22. Shai I, Schwarzfuchs D, Henkin Y, et al.;
Dietary Intervention Randomized Controlled
Trial (DIRECT) Group Weight loss with a low-
carbohydrate, Mediterranean, or low-fat diet.
N Engl J Med 2008;359:229–241
23. Qi Q, Xu M, Wu H, et al. IRS1 genotype
modulates metabolic syndrome reversion in re-
sponse to 2-year weight-loss diet intervention:
the POUNDS LOST trial. Diabetes Care 2013;36:
3442–3447
444 Gene-Diet Interaction and Insulin Resistance Diabetes Care Volume 38, March 2015
